|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.57 USD | -2.97% |
|
+1.13% | +3.02% |
| 06-03 | Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment | MT |
| 06-03 | Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial | DJ |
| Market Cap | 113B 98.27B 90.17B 84.84B 158B 10,814B 160B 1,072B 417B 5,230B 426B 417B 18,186B | P/E ratio 2026 * |
10.9x | P/E ratio 2027 * | 10.8x |
|---|---|---|---|---|---|
| Enterprise value | 142B 123B 113B 106B 198B 13,536B 201B 1,342B 522B 6,546B 533B 522B 22,764B | EV / Sales 2026 * |
3x | EV / Sales 2027 * | 2.93x |
| Free-Float |
69.8% | Yield 2026 * |
4.52% | Yield 2027 * | 4.65% |
Last Transcript: Bristol-Myers Squibb Company
| 1 day | +0.27% | ||
| 1 week | +1.13% | ||
| Current month | -2.82% | ||
| 1 month | -1.05% | ||
| 3 months | -7.83% | ||
| 6 months | +7.55% | ||
| Current year | +3.02% |
| 1 week | 54.31 |  | 57.82 |
| 1 month | 54.2 | | 60.25 |
| Current year | 52.06 | | 62.89 |
| 1 year | 42.52 | | 62.89 |
| 3 years | 39.35 | | 66.38 |
| 5 years | 39.35 | | 81.44 |
| 10 years | 39.35 | | 81.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 01/11/2023 | |
David Elkins
DFI | Director of Finance/CFO | 58 | 20/11/2019 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 55 | 01/04/2024 | |
Peter Arduini
BRD | Director/Board Member | 61 | 01/04/2016 |
Theodore Samuels
BRD | Director/Board Member | 71 | 21/02/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-03 | Fiscal year | EVP, Corporate Affairs | 19,956 | 0.0010% | ||
| 05-01 | Fiscal year | Executive/Senior Manager | 3,548 | 0.0002% | ||
| 04-01 | Sell | Chief Financial Officer | 30,000 | 0.0015% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.97% | +1.13% | +14.79% | -14.91% | 113B | |
| +1.57% | +6.19% | +49.26% | +157.85% | 1,025B | |
| -0.26% | +3.87% | +49.75% | +44.86% | 559B | |
| -1.83% | +4.76% | +17.51% | +62.07% | 394B | |
| -2.16% | +3.06% | +21.96% | +15.20% | 324B | |
| -1.05% | +3.78% | +51.35% | +8.34% | 295B | |
| -1.46% | +2.95% | +26.29% | +16.15% | 286B | |
| -0.47% | +3.35% | +19.69% | +29.51% | 270B | |
| -1.56% | -3.48% | -48.44% | -50.90% | 186B | |
| -1.10% | +5.04% | +19.08% | +56.61% | 187B | |
| Average | -0.52% | +2.90% | +22.12% | +32.48% | 363.97B | |
| Weighted average by Cap. | -0.38% | +3.93% | +32.01% | +63.38% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.31B 40.97B 37.59B 35.37B 65.88B 4,508B 66.91B 447B 174B 2,180B 178B 174B 7,582B | 46.22B 40.03B 36.73B 34.56B 64.36B 4,405B 65.37B 437B 170B 2,130B 174B 170B 7,408B |
| Net income | 10.55B 9.14B 8.39B 7.89B 14.7B 1,006B 14.93B 99.69B 38.8B 486B 39.63B 38.77B 1,692B | 10.26B 8.89B 8.15B 7.67B 14.29B 978B 14.51B 96.9B 37.71B 473B 38.52B 37.69B 1,644B |
| Net Debt | 28.56B 24.74B 22.7B 21.35B 39.77B 2,722B 40.39B 270B 105B 1,316B 107B 105B 4,578B | 22.03B 19.08B 17.51B 16.47B 30.68B 2,100B 31.16B 208B 81B 1,015B 82.74B 80.94B 3,531B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/06/26 | 55.57 $ | -2.97% | 12,344,654 |
| 05/06/26 | 57.27 $ | +1.18% | 9,575,913 |
| 04/06/26 | 56.60 $ | +3.44% | 12,659,116 |
| 03/06/26 | 54.72 $ | +0.48% | 11,540,668 |
| 02/06/26 | 54.46 $ | -0.89% | 13,739,876 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BMY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition